Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regression Models For Multivariate Count Data.

Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America·2017
Same author

Thermal Fluctuations of Ferroelectric Nanodomains in a Ferroelectric-Dielectric PbTiO_{3}/SrTiO_{3} Superlattice.

Physical review letters·2017
Same author

Purity assessment of ginsenoside Rg1 using quantitative <sup>1</sup>H nuclear magnetic resonance.

Journal of pharmaceutical and biomedical analysis·2017
Same author

Colistin Resistance in <i>Acinetobacter baumannii</i> MDR-ZJ06 Revealed by a Multiomics Approach.

Frontiers in cellular and infection microbiology·2017
Same author

Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences·2017
Same author

Interface Control of Ferroelectricity in an SrRuO<sub>3</sub> /BaTiO<sub>3</sub> /SrRuO<sub>3</sub> Capacitor and its Critical Thickness.

Advanced materials (Deerfield Beach, Fla.)·2017

Related Experiment Video

Updated: May 15, 2026

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
11:31

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System

Published on: August 8, 2012

Determining duration of HER2-targeted therapy using stem cell extinction models.

Lindsay Riley1, Hua Zhou, Kenneth Lange

  • 1Department of Biomathematics, School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.

Plos One
|January 4, 2013
PubMed
Summary

HER2-targeted therapy can eradicate breast cancer stem-like cells (BCSCs), even in early-stage treatment. Prolonged therapy duration is crucial for BCSC extinction, guiding clinical trials for optimal treatment strategies.

More Related Videos

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Related Experiment Videos

Last Updated: May 15, 2026

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
11:31

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System

Published on: August 8, 2012

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Area of Science:

  • Oncology
  • Mathematical Biology
  • Cancer Stem Cell Research

Background:

  • Trastuzumab enhances survival in HER2-overexpressing breast cancer.
  • Cancer stem-like cells (BCSCs) in tumors rely on HER2 signaling for self-renewal.
  • HER2-targeted therapy may impact BCSCs even if the bulk tumor doesn't overexpress HER2.

Purpose of the Study:

  • To develop a mathematical model for BCSC population dynamics.
  • To predict the optimal duration of HER2-targeted therapy in the adjuvant setting.
  • To guide clinical trials for HER2-targeted therapies.

Main Methods:

  • Quantified BCSC extinction time by varying therapy susceptibility.
  • Expanded the model using stochastic simulation to include tumor cells (TCs).
  • Examined the impact of cell plasticity on therapy duration.

Main Results:

  • Lower BCSC susceptibility and higher dedifferentiation rates necessitate longer therapy.
  • HER2-targeted therapy can eventually eradicate tumors in the adjuvant setting.
  • Therapy is effective if it has a modest impact on BCSCs, even if tumor size reduction is not significant.

Conclusions:

  • Results inform clinical trials on the necessary duration of targeted therapy to eradicate BCSCs.
  • Predictions address safety concerns regarding potential impacts on normal stem cells with prolonged therapy.